Asbestos Mesothelioma Mesothelioma Treatment
Mesothelioma Alerts Conventional Treatments Experimental Treatments Mesothelioma Clinical Trials Mesothelioma Treatment by Stage Ask Your Doctor Cancer Centers Leading Mesothelioma Physicians Mesothelioma Articles & Abstracts Review Studies Case Studies Etiological Studies Diagnostic Studies Therapy Studies Mesothelioma Resources
News About ELSS Top Mesothelioma Doctors

Dr. Robert N. Taub
New York, NY; Prominent mesothelioma doctor and director of Columbia’s Mesothelioma Center...

Dr. Valerie Rusch
New York, NY; Internationally recognized thoracic surgeon has led numerous research efforts to understand how patients respond to mesothelioma treatment...

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

First Name:

Last Name:

Address:

City:

ST:

Zip:

Home Phone:

Work Phone:

Cell Phone:

Email Address:

Have you or someone you know been diagnosed with mesothelioma?

Yes   No

Mesothelioma Treatment | Articles & Abstracts

Review Studies

A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.

Ann Oncol. 2006 Nov 27; [Epub ahead of print]
Yan TD, Welch L, Black D, Sugarbaker PH.
Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC.

BACKGROUND: In the past, diffuse malignant peritoneal mesothelioma (DMPM) was regarded as a preterminal condition. The length of survival was dependent upon the aggressive versus indolent biologic behavior of the neoplasm. The overall median survival was approximately 1 year after systemic chemotherapy. Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used as a treatment alternative, but the efficacy of this combined treatment remains to be established. PATIENTS AND METHODS: Searches for relevant studies published in peer-reviewed medical journals on CRS and PIC for DMPM before May 2006 were carried out on six databases. The reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies. Expert academic surgeons in Washington, DC, USA were asked whether they knew about any important unpublished data. Two investigators independently evaluated each study according to predefined criteria. The quality of each study was assessed. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies. RESULTS: Seven prospective observational studies from six tertiary institutions were available, allowing 240 DMPM patients for assessment. The median survival ranged from 34-92 months. The 1-, 3- and 5-year survival varied from 60% to 88%, 43% to 65% and 29% to 59%, respectively. The perioperative morbidity varied from 25% to 40% and mortality ranged from 0% to 8%. CONCLUSIONS: This systematic review evaluated the current evidence for CRS and PIC for DMPM. Seven observational studies were available for assessment, which demonstrated an improved overall survival, as compared to historical controls, using systemic chemotherapy and palliative surgery.

PMID: 17130182 [PubMed - as supplied by publisher]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.